Form 4: Apellis Pharmaceuticals Director Alec Machiels Reports Stock and Option Transactions

Director Alec Machiels of Apellis Pharmaceuticals reports acquisition of restricted stock units and stock options, along with indirect holdings through various entities.

Summary

• Alec Machiels, a director at Apellis Pharmaceuticals, reported several transactions involving the company's stock.
• On January 1, 2025, Machiels acquired 6,267 shares of common stock as restricted stock units, which will vest on the first anniversary of the grant date.
• He also acquired 11,199 stock options, vesting quarterly from the grant date and expiring seven years later.
• Machiels indirectly owns 250,000 shares through Bauhaus 1 LLC, where he is the managing member and trustee.
• Additionally, he indirectly owns 11,950 shares held by his spouse and 150,000 shares held in a spouse's trust where he is the trustee.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of insider transactions, which is neither positive nor negative. The transactions are expected and do not indicate any significant change in the company's outlook.

Positives

• The acquisition of restricted stock units and stock options aligns the director's interests with the company's performance.
• The vesting schedule of the stock options encourages long-term commitment from the director.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the holdings and transactions of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The reported transactions are typical for directors, including grants of restricted stock units and stock options as part of their compensation.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the director's holdings and alignment with company performance.

Key Dates

Keywords

Apellis Pharmaceuticals, insider trading, stock options, restricted stock units, beneficial ownership, director, Form 4